Home » FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
Incyte announced that the FDA has accepted for filing the new drug application (NDA) for Incyte’s lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis (MF).
MarketWatch
MarketWatch
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May